N@N

Immunovaccine Announces Results of 2011 AGM

^{Published on 2011-06-23 05:50:45 - Market Wire}
 

HALIFAX, June 23, 2011 /CNW/ - Immunovaccine Inc. (TSX-V: IMV) (the "Company" or "Immunovaccine"), a clinical stage vaccine developer, today announced the results of the Company's annual general meeting of shareholders (AGM) held on June 22, 2011.

At the AGM, the shareholders elected Brad Thompson, Ph.D., and Kimberly Stephens, C.A., as new directors and re-elected: Dr. William A. Cochrane, Wade K. Dawe, James W. Hall and Albert Scardino to serve on the Board of Directors until the next annual meeting of shareholders. Albert Scardino will also assume the duties of the non-executive Chair of the Board. Former directors Michael Kirby and Paul Kirkconnell did not stand for re-election.

"The Board and management wish to thank Mr. Kirby and Mr. Kirkconnell for their service and contributions to the Board," said Albert Scardino, Chair of Immunovaccine.

The shareholders approved all motions put forth at the meeting including the appointment of PricewaterhouseCoopers LLP, Chartered Accountants, as the Company's independent auditors.

Immunovaccine Inc. is focused on the commercialization of its patented DepoVax™ vaccine delivery platform and product candidates. Currently, the Company has developed two therapeutic cancer vaccine candidates for clinical trials. With the goal of developing premium therapeutic cancer and infectious disease vaccines, Immunovaccine continues to strengthen its vaccine pipeline through licensing and strategic partnerships with companies worldwide. [ www.imvaccine.com ]

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information.  Forward-looking statements are based on the estimates and opinions of management on the date the statements are made.  However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release. 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.